Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17252164 | GENETIC SELECTION MARKERS BASED ON ENZYMATIC ACTIVITIES OF THE PYRIMIDINE SALVAGE PATHWAY | December 2020 | December 2023 | Abandon | 36 | 0 | 1 | No | No |
| 15733848 | Gene Targeting | November 2020 | June 2024 | Abandon | 42 | 3 | 1 | No | No |
| 17059415 | LENTIVIRAL VECTOR AND METHOD FOR DELIVERING EXOGENOUS RNA BY THE LENTIVIRAL VECTOR | November 2020 | June 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17102031 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2020 | March 2021 | Allow | 4 | 0 | 0 | No | No |
| 17053538 | BIOSENSOR | November 2020 | September 2024 | Abandon | 47 | 1 | 0 | No | No |
| 17091931 | Compositions and Methods for Modulating Growth of a Genetically Modified Gut Bacterial Cell | November 2020 | October 2021 | Allow | 11 | 2 | 1 | No | No |
| 17052030 | VACCINE COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN-SPECIFIC VACCINATION | October 2020 | August 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17084020 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2020 | March 2021 | Allow | 4 | 0 | 0 | Yes | No |
| 17033255 | OPTIMIZED SMALL GUIDE RNAS AND METHODS OF USE | September 2020 | March 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17040856 | REVERSIBLY SWITCHABLE FLUORESCENT PROTEIN-BASED INDICATORS | September 2020 | May 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 16938739 | CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING | July 2020 | April 2021 | Allow | 8 | 0 | 0 | Yes | No |
| 16935023 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | July 2020 | February 2021 | Allow | 7 | 0 | 0 | Yes | No |
| 16935016 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | July 2020 | February 2021 | Allow | 60 | 0 | 0 | No | No |
| 16877372 | METHODS OF DIAGNOSING INFECTIOUS DISEASE PATHOGENS AND THEIR DRUG SENSITIVITY | May 2020 | May 2024 | Abandon | 48 | 1 | 1 | No | No |
| 16858333 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | April 2020 | August 2021 | Allow | 15 | 1 | 2 | Yes | No |
| 16818229 | METHODS AND COMPOSITIONS FOR TREATING TUMOR CELLS | March 2020 | August 2022 | Abandon | 29 | 4 | 1 | No | No |
| 16791968 | GENOMIC SEQUENCE MODIFICATION METHOD FOR SPECIFICALLY CONVERTING NUCLEIC ACID BASES OF TARGETED DNA SEQUENCE, AND MOLECULAR COMPLEX FOR USE IN SAME | February 2020 | January 2023 | Allow | 35 | 3 | 0 | No | No |
| 16737793 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | January 2020 | December 2023 | Abandon | 47 | 3 | 1 | No | Yes |
| 16608146 | COMPOSITIONS AND METHODS OF DUAL POISON-ANTIDOTE MEIOTIC DRIVERS | October 2019 | May 2024 | Allow | 55 | 2 | 1 | Yes | No |
| 16500970 | ANTIBODIES HAVING CONDITIONAL AFFINITY AND METHODS OF USE THEREOF | October 2019 | March 2024 | Abandon | 54 | 0 | 1 | No | No |
| 16588754 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | September 2019 | October 2023 | Abandon | 49 | 4 | 2 | Yes | Yes |
| 16486892 | COMPOSITIONS AND METHODS FOR INCREASED PROTEIN PRODUCTION IN BACILLUS LICHENIFORMIS | August 2019 | August 2023 | Allow | 48 | 1 | 1 | Yes | No |
| 16533928 | YEAST STRAINS WITH SELECTED OR ALTERED MITOTYPES AND METHODS OF MAKING AND USING THE SAME | August 2019 | February 2024 | Allow | 54 | 4 | 1 | Yes | No |
| 16483979 | USE OF MICROBIAL CONSORTIA IN THE PRODUCTION OF MULTI-PROTEIN COMPLEXES | August 2019 | August 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16515512 | METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES | July 2019 | December 2022 | Abandon | 41 | 0 | 1 | No | No |
| 16513560 | TREATMENT OF NEUROPATHY WITH IGF-1-ENCODING DNA CONSTRUCTS AND HGF-ENCODING DNA CONSTRUCTS | July 2019 | November 2022 | Abandon | 40 | 4 | 1 | Yes | No |
| 16415605 | SEC Modified Strains for Improved Secretion of Recombinant Proteins | May 2019 | December 2022 | Allow | 43 | 3 | 1 | Yes | No |
| 16364002 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | March 2019 | January 2024 | Abandon | 58 | 7 | 1 | Yes | No |
| 16335512 | CONSTRUCTS FOR CONTINUOUS MONITORING OF LIVE CELLS | March 2019 | February 2023 | Allow | 47 | 1 | 1 | Yes | No |
| 16272978 | Methods of Detecting Bladder Cancer | February 2019 | May 2024 | Abandon | 60 | 5 | 1 | No | Yes |
| 16267693 | MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES | February 2019 | August 2022 | Allow | 43 | 3 | 1 | Yes | No |
| 16322719 | ULTRASPECIFIC RIBOREGULATORS HAVING ROBUST SINGLE-NUCLEOTIDE SPECIFICITY AND IN VITRO AND IN VIVO USES THEREOF | February 2019 | February 2023 | Allow | 48 | 1 | 1 | Yes | No |
| 16260630 | METHODS OF ENHANCING CHROMOSOMAL HOMOLOGOUS RECOMBINATION | January 2019 | December 2022 | Allow | 47 | 3 | 1 | Yes | No |
| 16320350 | COMPOSITIONS COMPRISING A LECITHIN CHOLESTEROL ACYLTRANSFERASE VARIANT AND USES THEREOF | January 2019 | September 2023 | Allow | 56 | 1 | 1 | Yes | No |
| 16256003 | STRUCTURE-GUIDED CHEMICAL MODIFICATION OF GUIDE RNA AND ITS APPLICATIONS | January 2019 | March 2022 | Abandon | 38 | 2 | 0 | No | Yes |
| 16248899 | Genome-Scale Engineering of Cells with Single Nucleotide Precision | January 2019 | September 2023 | Abandon | 56 | 5 | 0 | No | Yes |
| 16226963 | Enzymatic Processes for Synthesizing RNA Containing Certain Non-Standard Nucleotides | December 2018 | October 2020 | Allow | 22 | 1 | 0 | No | No |
| 16310701 | POTENT AND BALANCED BIDIRECTIONAL PROMOTER | December 2018 | December 2020 | Allow | 24 | 2 | 0 | No | No |
| 16201736 | SINGLE-VECTOR TYPE I VECTORS | November 2018 | August 2023 | Allow | 57 | 7 | 1 | No | No |
| 16195240 | SITE-SPECIFIC NUCLEASE SINGLE-CELL ASSAY TARGETING GENE REGULATORY ELEMENTS TO SILENCE GENE EXPRESSION | November 2018 | June 2022 | Abandon | 42 | 2 | 1 | No | No |
| 16192207 | WHOLE-CELL CATALYTIC SYSTEM AND APPLICATIONS THEREOF | November 2018 | September 2021 | Allow | 34 | 2 | 0 | Yes | No |
| 16189418 | MICROBIAL PRODUCTION OF PURE SINGLE STRANDED NUCLEIC ACIDS | November 2018 | December 2020 | Allow | 25 | 1 | 1 | Yes | No |
| 16099749 | GENETICALLY ENCODED BIOSENSORS FOR DETECTION OF POLYKETIDES | November 2018 | June 2022 | Allow | 43 | 1 | 1 | Yes | No |
| 16170049 | MIXTURE OF CELL EXTRACT AND METHOD FOR SITE-DIRECTED CLONING | October 2018 | September 2021 | Allow | 35 | 2 | 1 | No | No |
| 16095147 | GENE EDITING REAGENTS WITH REDUCED TOXICITY | October 2018 | June 2023 | Abandon | 56 | 2 | 1 | No | No |
| 16094788 | MEANS AND METHODS FOR INACTIVATING THERAPEUTIC DNA IN A CELL | October 2018 | September 2024 | Abandon | 60 | 6 | 1 | No | No |
| 16094874 | HIGH cAMP YIELDING YEAST STRAIN AND USE THEREOF | October 2018 | February 2023 | Allow | 52 | 2 | 1 | Yes | No |
| 16093575 | REPAIRING COMPOUND HETEROZYGOUS RECESSIVE MUTATIONS BY ALLELE EXCHANGE | October 2018 | May 2023 | Allow | 55 | 3 | 1 | Yes | No |
| 16147741 | HOST CELLS WITH ENHANCED PROTEIN EXPRESSION EFFICIENCY AND USES THEREOF | September 2018 | September 2024 | Abandon | 60 | 8 | 1 | No | No |
| 16136902 | SHUTTLE VECTOR, PROKARYOTIC HOST CELLS, KIT, AND METHOD FOR PRODUCING PROTEINS | September 2018 | July 2020 | Allow | 22 | 1 | 1 | No | No |
| 16124127 | Promoter useful for high expression of a heterologous gene of interest in Aspergillus niger | September 2018 | March 2022 | Allow | 43 | 1 | 0 | Yes | No |
| 16080315 | MYO1A FOR PREDICTING CONVERSION OF ACUTE PAIN INTO CHRONIC PAIN AND USE OF MYO1A FOR THERAPY OF PAIN | August 2018 | July 2021 | Allow | 35 | 2 | 1 | Yes | No |
| 16109657 | ENGINEERED CRISPR-CAS9 NUCLEASES WITH ALTERED PAM SPECIFICITY | August 2018 | December 2021 | Allow | 39 | 1 | 1 | Yes | No |
| 16049042 | RNA CLEAVAGE-INDUCED TRANSCRIPT STABILIZER AND USES THEREOF | July 2018 | June 2023 | Allow | 58 | 2 | 1 | Yes | No |
| 16047862 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH OF A GENETICALLY MODIFIED GUT BACTERIAL CELL | July 2018 | May 2022 | Abandon | 45 | 4 | 1 | Yes | Yes |
| 16034089 | METHODS AND COMPOSITION FOR THE PRODUCTION OF SEQUENCE SPECIFIC ANTIMICROBIALS | July 2018 | November 2022 | Abandon | 52 | 2 | 1 | No | No |
| 16069266 | BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES | July 2018 | September 2024 | Abandon | 60 | 4 | 2 | No | No |
| 16068230 | METHOD OF MODULATING SURVIVAL AND STEMNESS OF CANCER STEM CELLS BY MDA-9/SYNTENIN (SDCBP) | July 2018 | May 2022 | Abandon | 46 | 3 | 0 | Yes | No |
| 16023525 | YEAST STRAINS AND METHODS FOR PRODUCING COLLAGEN | June 2018 | December 2021 | Allow | 42 | 3 | 1 | Yes | No |
| 16019218 | METHODS AND COMPOSITIONS RELATING TO ASSAYS FOR INHIBITORS OF ASSOCIATION BETWEEN ELK1 AND STEROID HORMONE RECEPTORS | June 2018 | July 2022 | Abandon | 49 | 4 | 1 | Yes | No |
| 16009735 | MATERIALS AND METHODS FOR IDENTIFYING GYRASE INHIBITORS | June 2018 | January 2023 | Allow | 55 | 4 | 1 | Yes | No |
| 16006594 | CELL LINE EXPRESSING SINGLE CHAIN FACTOR VIII POLYPEPTIDES AND USES THEREOF | June 2018 | May 2023 | Abandon | 59 | 2 | 1 | Yes | Yes |
| 16060375 | PROMOTERS FROM CORYNEBACTERIUM GLUTAMICUM | June 2018 | November 2021 | Allow | 41 | 1 | 1 | Yes | No |
| 15994002 | PHAGE ENGINEERING: PROTECTION BY CIRCULARIZED INTERMEDIATE | May 2018 | August 2022 | Allow | 51 | 2 | 1 | Yes | No |
| 15775892 | PHAGE DISPLAY VECTORS AND METHODS OF USE | May 2018 | March 2021 | Allow | 34 | 2 | 0 | No | No |
| 15769331 | Methods and Compositions for Inducibly Targeting Chromatin Effectors | April 2018 | July 2021 | Abandon | 39 | 2 | 1 | No | No |
| 15767020 | GENOMIC COMBINATORIAL SCREENING PLATFORM | April 2018 | December 2021 | Abandon | 44 | 4 | 1 | No | No |
| 15936293 | QUANTITATIVE ASSESSMENT FOR CAP EFFICIENCY OF MESSENGER RNA | March 2018 | February 2022 | Allow | 47 | 3 | 1 | Yes | No |
| 15762564 | Gene Expression Cassette And Product Thereof | March 2018 | June 2023 | Abandon | 60 | 4 | 1 | No | No |
| 15759709 | METHOD FOR IDENTIFYING BIOACTIVE PROTEIN, AND BIOACTIVE PROTEIN OBTAINED BY SAID METHOD | March 2018 | March 2024 | Abandon | 60 | 7 | 1 | Yes | No |
| 15757240 | DETECTION OF GENE LOCI WITH CRISPR ARRAYED REPEATS AND/OR POLYCHROMATIC SINGLE GUIDE RIBONUCLEIC ACIDS | March 2018 | March 2022 | Allow | 48 | 2 | 1 | Yes | No |
| 15756875 | SYSTEMS AND METHODS FOR SELECTION OF GRNA TARGETING STRANDS FOR CAS9 LOCALIZATION | March 2018 | June 2023 | Abandon | 60 | 6 | 1 | Yes | No |
| 15896390 | CAPSID-MODIFIED RAAV VECTOR COMPOSITIONS HAVING IMPROVED TRANSDUCTION EFFICIENCIES, AND METHODS OF USE | February 2018 | March 2022 | Abandon | 49 | 3 | 0 | No | No |
| 15878698 | CONSTRUCTS AND METHODS FOR GENOME EDITING AND GENETIC ENGINEERING OF FUNGI AND PROTISTS | January 2018 | August 2020 | Allow | 31 | 4 | 0 | Yes | No |
| 15744505 | NUCLEASE-INDEPENDENT TARGETED GENE EDITING PLATFORM AND USES THEREOF | January 2018 | December 2021 | Allow | 47 | 4 | 0 | Yes | No |
| 15744685 | CHROMOSOME NEIGHBORHOOD STRUCTURES AND METHODS RELATING THERETO | January 2018 | November 2023 | Abandon | 60 | 3 | 1 | Yes | No |
| 15860408 | SYSTEMS AND METHODS FOR DETECTION OF GENOMIC COPY NUMBER CHANGES | January 2018 | September 2022 | Abandon | 56 | 4 | 0 | No | No |
| 15850288 | Smart CAR Devices, DE CAR Polypeptides, Side CARs and Uses Thereof | December 2017 | October 2022 | Allow | 58 | 5 | 1 | Yes | No |
| 15738545 | RETROVIRAL VECTORS CONTAINING A REVERSE ORIENTATION HUMAN UBIQUITIN C PROMOTER | December 2017 | April 2021 | Abandon | 40 | 0 | 1 | No | No |
| 15579570 | VECTORS | December 2017 | March 2023 | Allow | 60 | 4 | 1 | Yes | No |
| 15831230 | COMPOSITIONS AND METHODS FOR ENHANCING GENE EXPRESSION | December 2017 | April 2023 | Allow | 60 | 4 | 1 | Yes | No |
| 15559753 | CRISPR/CAS9 BASED ENGINEERING OF ACTINOMYCETAL GENOMES | September 2017 | July 2021 | Abandon | 46 | 0 | 1 | No | No |
| 15554552 | Constitutive Yeast LLP Promotor-Based Expression Systems | August 2017 | August 2021 | Allow | 47 | 3 | 1 | Yes | No |
| 15548983 | METHOD OF PRODUCING YEAST MUTANTS AND THE USE THEREOF | August 2017 | February 2021 | Abandon | 42 | 1 | 0 | No | No |
| 15665018 | MINIMIZING ERRORS USING URACIL-DNA-N-GLYCOSYLASE | July 2017 | July 2022 | Abandon | 59 | 7 | 0 | Yes | No |
| 15536933 | FUNGAL GENOME MODIFICATION SYSTEMS AND METHODS OF USE | June 2017 | April 2022 | Allow | 58 | 4 | 1 | No | No |
| 15488832 | Salivary Transcriptomics and Proteomic Biomarkers for Breast Cancer Detection | April 2017 | July 2021 | Abandon | 51 | 5 | 1 | No | No |
| 15440575 | Systems and Methods for Expression-Based Classification of Thyroid Tissue | February 2017 | October 2021 | Abandon | 56 | 4 | 1 | No | No |
| 15402724 | LIGAND SCREENING AND DISCOVERY | January 2017 | November 2022 | Abandon | 60 | 8 | 0 | Yes | No |
| 15334341 | Transcription Activator-Like Effectors | October 2016 | April 2022 | Allow | 60 | 7 | 0 | Yes | No |
| 15303974 | VECTOR AND METHOD FOR EXPRESSING MOLECULES OF INTEREST IN A BACTERIAL CELL | October 2016 | November 2021 | Abandon | 60 | 4 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GROOMS, TIFFANY NICOLE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GROOMS, TIFFANY NICOLE works in Art Unit 1636 and has examined 91 patent applications in our dataset. With an allowance rate of 53.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner GROOMS, TIFFANY NICOLE's allowance rate of 53.8% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GROOMS, TIFFANY NICOLE receive 2.77 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by GROOMS, TIFFANY NICOLE is 47 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +49.2% benefit to allowance rate for applications examined by GROOMS, TIFFANY NICOLE. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.8% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.8% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 52.6% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.2% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.